Effect of Acarbose, Sitagliptin and combination therapy on blood glucose, insulin, and incretin hormone concentrations in experimentally induced postprandial hyperglycemia of healthy cats
Effect of Acarbose, Sitagliptin and combination therapy on blood glucose, insulin, and incretin hormone concentrations in experimentally induced postprandial hyperglycemia of healthy cats
复制标题
DOI：
10.1016/j.rvsc.2016.04.001
复制
发表时间：
2016-06-01
影响因子：
2.4
通讯作者：
Sako, Toshinori
中科院分区：
文献类型：
--
作者：
Mori, Akihiro;Ueda, Kaori;Sako, Toshinori
阿卡波糖（AC）和西格列汀（STGP）是目前单独使用或与人类糖尿病（2型）患者联合使用的口服降糖药。AC已用于糖尿病猫，但迄今尚未STGP。因此，本研究的目的是通过观察AC或STGP对短期餐后血糖、胰岛素和肠促胰岛素激素的影响，确定AC或STGP单独或联合用于糖尿病猫的潜在用途（活性胰高血糖素样肽-1（GLP-1）和总葡萄糖依赖性促胰岛素多肽（GIP））浓度，在摄入含麦芽糖的食物后。所有治疗都倾向于（p < 0.10; 5-7.5%降低），以降低餐后血糖曲线下面积（AUC），并伴随显著降低（p < 0.05，35-45%）。同时，与AC或无治疗相比，STGP（高100%）和组合治疗（高130%）观察到餐后活性GLP-1 AUC显著增加（p < 0.05）。最后，与对照组相比，STGP（减少21%）和联合治疗（减少7%）观察到餐后总GIP AUC显着降低（p < 0.05）。总体而言，AC、STGP或联合给药可显著诱导健康猫的胰岛素和肠促胰岛素激素水平的餐后正向变化。增加活性GLP-1和降低餐后高血糖似乎是联合治疗的主要机制。考虑到AC和STGP诱导较低葡萄糖和胰岛素水平的不同但互补的作用机制，这两种药物的联合治疗为未来治疗糖尿病猫提供了巨大的潜力。(C)2016爱思唯尔有限公司版权所有
Acarbose (AC) and Sitagliptin (STGP) are oral hypoglycemic agents currently used either alone or in conjunction with human diabetic (Type 2) patients. AC has been used with diabetic cats, but not STGP thus far. Therefore, the objective of this study was to determine the potential use of AC or STGP alone and in combination for diabetic cats, by observing their effect on short-term post-prandial serum glucose, insulin, and incretin hormone (active glucagon-like peptide-1 (GLP-1) and total glucose dependent insulinotropic polypeptide (GIP)) concentrations in five healthy cats, following ingestion of a meal with maltose.All treatments tended (p < 0.10; 5-7.5% reduction) to reduce postprandial glucose area under the curve (AUC), with an accompanying significant reduction (p < 0.05, 35-45%) in postprandial insulin AUC as compared to no treatment. Meanwhile, a significant increase (p < 0.05) in postprandial active GLP-1 AUC was observed with STGP (100% higher) and combined treatment (130% greater), as compared to either AC or no treatment. Lastly, a significant reduction (p < 0.05) in postprandial total GIP AUC was observed with STGP (21% reduction) and combined treatment (7% reduction) as compared to control. Overall, AC, STGP, or combined treatment can significantly induce positive post-prandial changes to insulin and incretin hormone levels of healthy cats. Increasing active GLP-1 and reducing postprandial hyperglycemia appear to be the principal mechanisms of combined treatment. Considering the different, but complementary mechanisms of action by which AC and STGP induce lower glucose and insulin levels, combination therapy with both these agents offers great potential for treating diabetic cats in the future. (C) 2016 Elsevier Ltd. All rights reserved.